InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INM InMed Pharmaceuticals Inc

Market Closed 12-12 16:00:00 EST

1.43

+0.04

+2.88%

盘后1.33

-0.10-6.99%

19:39 EST

High1.48	Low1.35	Vol386.51K
Open1.40	D1 Closing1.39	Amplitude9.33%
Mkt Cap4.01M	Tradable Cap4.00M	Total Shares2.80M
T/O552.44K	T/O Rate13.81%	Tradable Shares2.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INM","market":"US","secType":"STK","nameCN":"InMed Pharmaceuticals Inc","latestPrice":1.43,"timestamp":1765573200000,"preClose":1.39,"halted":0,"volume":386510,"hourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.43,"latestTime":"19:39 EST","volume":77526,"amount":108466.8248,"timestamp":1765586357850},"delay":0,"floatShares":2799500,"shares":2804186,"eps":-8.362969,"marketStatus":"Market Closed","change":0.04,"latestTime":"12-12 16:00:00 EST","open":1.4,"high":1.48,"low":1.3503,"amount":552435.534967,"amplitude":0.093309,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.362969,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.39,"preHourTrading":{"tag":"盘前","latestPrice":1.3932,"preClose":1.39,"latestTime":"09:27 EST","volume":30100,"amount":42821.56634,"timestamp":1765549670015},"postHourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.43,"latestTime":"19:39 EST","volume":77526,"amount":108466.8248,"timestamp":1765586357850},"volumeRatio":2.4111829327643948},"requestUrl":"/m/hq/s/INM","defaultTab":"news","newsList":[{"id":"2584814511","title":"Why Did Vivakor Shares Surge 17% After Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584814511","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584814511?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:55","pubTimestamp":1763628900,"startTime":"0","endTime":"0","summary":"Vivakor shares jumped 17% in after-hours trading after the company reported widening losses and rising interest expenses.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/20/Market-Prudence-To-Increase-Amid-Growing.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/20/Market-Prudence-To-Increase-Amid-Growing.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48969121/why-did-vivakor-shares-surge-17-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48969121/why-did-vivakor-shares-surge-17-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4120","BK4144","VIVK","INM","BK4007"],"gpt_icon":0},{"id":"2584183421","title":"What's Driving InMed's (INM) 22% After-Hours Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584183421","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584183421?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:28","pubTimestamp":1763623737,"startTime":"0","endTime":"0","summary":"InMed shares jumped 22% in after-hours trading after the company reported encouraging large-animal study results for its Alzheimer&#39;s drug candidate INM-901.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48968515/whats-driving-inmeds-inm-22-after-hours-surge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4590","GLP","BK4144","INM"],"gpt_icon":0},{"id":"2584979338","title":"InMed Pharmaceuticals Completes Key Study for INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584979338","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584979338?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:51","pubTimestamp":1763589103,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) just unveiled an announcement. On November 18, 2025, InMed Pharmaceuticals announced the successful completion of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-completes-key-study-for-inm-901?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-completes-key-study-for-inm-901?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2584893095","title":"InMed Completes Key Pharmacokinetic Studies for Alzheimer’s Candidate INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584893095","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584893095?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:14","pubTimestamp":1763471651,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) has provided an update. InMed Pharmaceuticals announced the successful completion of pharmacokinetic studies for i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-completes-key-pharmacokinetic-studies-for-alzheimers-candidate-inm-901?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-completes-key-pharmacokinetic-studies-for-alzheimers-candidate-inm-901?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2584932967","title":"InMed Pharmaceuticals Completes Large Animal Study for Alzheimer's Drug Candidate INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584932967","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584932967?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:31","pubTimestamp":1763469066,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate, INM-901. The company reported that the oral formulation of INM-901 demonstrated a favorable bioavailability profile and achieved anticipated therapeutic levels of systemic exposure over a seven-day dosing period. Neurological assessments found no adverse neural or behavioral effects. These results, which have already been obtained, will support the design and planning of first-in-human clinical trials. InMed is preparing for a pre-IND meeting with the FDA and advancing further studies to support an IND submission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2hFfTp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2581445045","title":"InMed Pharmaceuticals reports $1.1 million in BayMedica revenues for Q1 fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581445045","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581445045?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:51","pubTimestamp":1762465916,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. reported cash and cash equivalents of $9.3 million as of September 30, 2025, down from $11.1 million at the end of June 2025. Short-term investments were $42.9 thousand, and accounts receivable totaled $343.5 thousand. Inventories stood at $890.8 thousand. General and administrative expenses were $1.5 million for the three months ended September 30, 2025, and are expected to remain stable for the remainder of fiscal 2026. Research and development expenses decreased due to reduced spending on external contractors and compensation but are anticipated to increase as preclinical and IND-enabling work on lead program INM-901 advances. The company expects available cash to fund planned operations into the fourth quarter of calendar year 2026. Business developments include progress toward clinical readiness for INM-901, a small-molecule therapy targeting multiple pathways associated with Alzheimer's disease, and the addition of two new directors to the board.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9qKrrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2578652899","title":"InMed Pharmaceuticals Inc. Announces Date for Upcoming Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578652899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578652899?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:55","pubTimestamp":1761339326,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has announced that it will hold its annual general and special meeting of shareholders virtually on December 17, 2025. Shareholders will have the opportunity to vote on key matters relating to the company. The management information circular with detailed information about the meeting and the matters to be addressed is available on the company's website, as well as through regulatory filings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL8pR5Ng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2578547730","title":"InMed Pharmaceuticals Files Amendment to Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2578547730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578547730?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:06","pubTimestamp":1761336368,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has filed an amendment to its annual report on Form 10-K/A for the fiscal year ended June 30, 2025. The amendment includes information previously omitted from the original filing, specifically Items 10, 11, 12, 13, and 14 of Part III of Form 10-K, as the company will not file a definitive proxy statement within the required timeframe. Additionally, new certifications from the principal executive officer and principal financial officer have been filed as exhibits. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL94bp2w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2577587295","title":"InMed Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director John Steven Bathery","url":"https://stock-news.laohu8.com/highlight/detail?id=2577587295","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577587295?lang=en_us&edition=fundamental","pubTime":"2025-10-24 07:32","pubTimestamp":1761262320,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names John Steven Bathery as a director and the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL7V4pKc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2576093471","title":"InMed Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director Neil Klompas","url":"https://stock-news.laohu8.com/highlight/detail?id=2576093471","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576093471?lang=en_us&edition=fundamental","pubTime":"2025-10-18 08:34","pubTimestamp":1760747661,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Neil A. Klompas as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251018:nNDL58XHnG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2575874646","title":"InMed Pharmaceuticals Appoints John Bathery to Board of Directors; Bryan Baldasare to Step Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2575874646","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575874646?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:31","pubTimestamp":1760617875,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has appointed John Bathery to its Board of Directors, effective immediately. Bathery brings over 30 years of experience in the pharmaceutical industry, including leadership in global business development and corporate partnerships. The company also announced that Bryan Baldasare will not stand for re-election at the upcoming Annual General Meeting in December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on October 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL1wKtpy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2575295519","title":"InMed Pharmaceuticals Appoints Neil Klompas to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2575295519","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575295519?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:01","pubTimestamp":1760436093,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has announced the appointment of Neil Klompas, CPA, CA, to its Board of Directors. Klompas brings over 30 years of experience in healthcare and biotechnology, including key leadership roles at Zymeworks Inc. He currently serves as CEO of Augerex Life Science Corp and holds board positions at NervGen Pharma and HTuO Biosciences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL4KNXB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007","BK4139","ZYME"],"gpt_icon":0},{"id":"2569790783","title":"InMed Pharmaceuticals Reports Fiscal 2025 Results: Sales Increase 8% to $4.9M, Net Loss Widens to $8.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2569790783","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569790783?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:31","pubTimestamp":1758630671,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has announced its financial results for the fiscal year ending June 30, 2025. The company reported sales of $4.9 million in its BayMedica segment, marking an increase of $0.34 million, or 8%, compared to the previous year. The net loss for the company was recorded at $8.2 million, compared to a net loss of $7.7 million for the previous fiscal year. Research and development expenses decreased to $2.9 million from $3.2 million in the previous year, while general and administrative expenses increased to $6.6 million from $5.8 million. The company maintains a cash position of $11.1 million, which it expects will support its pharmaceutical developments into the fourth quarter of calendar year 2026. Additionally, InMed continued to advance its pharmaceutical pipeline, particularly with the INM-901 program, which targets multiple biological pathways related to Alzheimer's disease. The company also reported progress in the development of INM-089 for the treatment of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDLb2D81r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2569790207","title":"InMed Pharmaceuticals FY Net Income USD -8.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2569790207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569790207?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:30","pubTimestamp":1758630623,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nPLX330770:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2565500584","title":"InMed Pharmaceuticals Inc. to Participate in H.C. Wainwright Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2565500584","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565500584?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:02","pubTimestamp":1757325767,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc., a company focused on developing drug candidates for diseases with high unmet medical needs, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. During the event, InMed's Chief Operating Officer, Michael Woudenberg, will present updates on the company's pipeline, including recent data from their leading pharmaceutical program INM-901 for treating Alzheimer's.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL1qQF6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2565567993","title":"InMed Pharmaceuticals Inc. Releases Corporate Presentation from H.C. Wainwright 27th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2565567993","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565567993?lang=en_us&edition=fundamental","pubTime":"2025-09-06 01:33","pubTimestamp":1757093634,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on September 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLblWBnP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2554775562","title":"InMed Pharmaceuticals Unveils Promising Preclinical Data for INM-901 at Alzheimer's Association International Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2554775562","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554775562?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:01","pubTimestamp":1753700515,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Unveils Promising Preclinical Data for INM-901 at Alzheimer's Association International Conference 2025. InMed Pharmaceuticals Inc. has announced the presentation of new preclinical data from its INM-901 program at the Alzheimer's Association International Conference  2025. The study focuses on INM-901, a proprietary small molecule drug candidate targeting multiple biological pathways in Alzheimer's disease. The research highlights long-term treatment results in an advanced 5xFAD mouse model, demonstrating improvements in cognitive function, anxiety-related behavior, and sensory responsiveness. Key findings include INM-901's anti-inflammatory action, neuroprotective effects, and promotion of neuronal regeneration. The presentation is scheduled for the conference taking place from July 27-31, 2025, in Toronto, Canada, with a scientific poster detailing the study results. The data will be made available on InMed's website following the event.Disclaimer: This news br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL4yDhTv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2548010062","title":"BRIEF-Inmed Pharmaceuticals Enters Agreement To Sell 1.9 Million Shares At $2.561 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2548010062","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548010062?lang=en_us&edition=fundamental","pubTime":"2025-07-01 04:36","pubTimestamp":1751315761,"startTime":"0","endTime":"0","summary":"BRIEF-Inmed Pharmaceuticals Enters Agreement To Sell 1.9 Million Shares At $2.561 EachJune 30  - InMed Pharmaceuticals Inc INM.O:INMED PHARMACEUTICALS INC - ON JUNE 24 ENTERS AGREEMENT TO SELL 1.9 MILLION SHARES AT $2.561 EACH - SEC FILINGFurther company coverage: INM.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX11W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2548010568","title":"InMed Pharmaceuticals Secures $5 Million Through Private Placement Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2548010568","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548010568?lang=en_us&edition=fundamental","pubTime":"2025-07-01 04:16","pubTimestamp":1751314598,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc., a company specializing in the development of small molecule drug candidates for diseases with high unmet medical needs, has announced a $5 million private placement. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 common shares and short-term preferred investment options to purchase the same number of common shares. These shares are priced at $2.561 each, with the associated options exercisable at $2.436 per share. H.C. Wainwright & Co. served as the exclusive placement agent for this offering. The gross proceeds are expected to be approximately $5 million, with potential additional proceeds of $4.75 million if the options are fully exercised. The company plans to use the funds to advance its pipeline development, support sales through its subsidiary BayMedica LLC, and for general working capital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLc1xdy5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2546217507","title":"InMed Pharmaceuticals Inc. Secures $5 Million Through Private Placement with Institutional Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2546217507","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546217507?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:01","pubTimestamp":1750852911,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing proprietary small molecule drug candidates, has announced a $5 million private placement priced at-the-market under Nasdaq rules. The company has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares and short-term preferred investment options to purchase an equal number of common shares. The securities were offered in a private placement under Section 4 of the Securities Act of 1933 and Regulation D. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The funds will support the development of InMed's pharmaceutical drug candidates, commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and general working capital. The offering is expected to close around June 25, 2025, pending customary closing conditions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL7v3k6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inmedpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1734},{"period":"3month","weight":-0.3318},{"period":"6month","weight":-0.4348},{"period":"1year","weight":-0.7223},{"period":"ytd","weight":-0.6983}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.074175},{"month":2,"riseRate":0.4,"avgChangeRate":-0.077696},{"month":3,"riseRate":0.2,"avgChangeRate":-0.164852},{"month":4,"riseRate":0.6,"avgChangeRate":0.072322},{"month":5,"riseRate":0.4,"avgChangeRate":-0.055462},{"month":6,"riseRate":0.4,"avgChangeRate":-0.082897},{"month":7,"riseRate":0.2,"avgChangeRate":-0.134974},{"month":8,"riseRate":0.2,"avgChangeRate":0.013552},{"month":9,"riseRate":0.2,"avgChangeRate":-0.118637},{"month":10,"riseRate":0.2,"avgChangeRate":-0.198876},{"month":11,"riseRate":0.2,"avgChangeRate":-0.092328},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.085648}],"exchange":"NASDAQ","name":"InMed Pharmaceuticals Inc","nameEN":"InMed Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"InMed Pharmaceuticals Inc,INM,InMed Pharmaceuticals Inc股票,InMed Pharmaceuticals Inc股票老虎,InMed Pharmaceuticals Inc股票老虎国际,InMed Pharmaceuticals Inc行情,InMed Pharmaceuticals Inc股票行情,InMed Pharmaceuticals Inc股价,InMed Pharmaceuticals Inc股市,InMed Pharmaceuticals Inc股票价格,InMed Pharmaceuticals Inc股票交易,InMed Pharmaceuticals Inc股票购买,InMed Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}